Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT 3-armed trial	491 people with chronic hepatitis C virus (HCV) mixed genotype and persistently normal alanine aminotransferase levels	Proportion of people reporting an adverse effect 204/212 (96%) with peginterferon plus ribavirin for 24 weeks 0/69 (0%) with no treatment	Significance not assessed
RCT 3-armed trial	491 people with chronic hepatitis C virus (HCV) mixed genotype and persistently normal alanine aminotransferase levels	Proportion of people reporting an adverse effect 206/210 (98%) with peginterferon plus ribavirin for 48 weeks 0/69 (0%) with no treatment	Significance not assessed
RCT 3-armed trial	491 people with chronic hepatitis C virus (HCV) mixed genotype and persistently normal alanine aminotransferase levels	Proportion of people with headache 93/212 (44%) with peginterferon plus ribavirin for 24 weeks 5/69 (7%) with no treatment	Significance not assessed
RCT 3-armed trial	491 people with chronic hepatitis C virus (HCV) mixed genotype and persistently normal alanine aminotransferase levels	Proportion of people with headache 117/210 (56%) with peginterferon plus ribavirin for 48 weeks 5/69 (7%) with no treatment	Significance not assessed
RCT 3-armed trial	491 people with chronic hepatitis C virus (HCV) mixed genotype and persistently normal alanine aminotransferase levels	Proportion of people with fatigue 109/212 (51%) with peginterferon plus ribavirin for 24 weeks 12/69 (17%) with no treatment	Significance not assessed
RCT 3-armed trial	491 people with chronic hepatitis C virus (HCV) mixed genotype and persistently normal alanine aminotransferase levels	Proportion of people with fatigue 107/210 (51%) with peginterferon plus ribavirin for 48 weeks 12/69 (17%) with no treatment	Significance not assessed
RCT 3-armed trial	491 people with chronic hepatitis C virus (HCV) mixed genotype and persistently normal alanine aminotransferase levels	Proportion of people with myalgia 81/212 (38%) with peginterferon plus ribavirin for 24 weeks 5/69 (7%) with no treatment	Significance not assessed
RCT 3-armed trial	491 people with chronic hepatitis C virus (HCV) mixed genotype and persistently normal alanine aminotransferase levels	Proportion of people with myalgia 93/210 (44%) with peginterferon plus ribavirin for 48 weeks 5/69 (7%) with no treatment	Significance not assessed